国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2009年
1期
56-59
,共4页
通心络胶囊%华法林%阿司匹林:心房颤动%脑栓塞
通心絡膠囊%華法林%阿司匹林:心房顫動%腦栓塞
통심락효낭%화법림%아사필림:심방전동%뇌전새
Tongxinluo capsule%Warfarin%Aspirin%Cerebral thromboembolism%Atrial fi-brillation
目的 比较通心络胶囊联合阿司匹林、阿司匹林和华法林预防心房颤动(AF)患者脑栓塞的疗效和不良反应.方法 AF患者450例,随机分为通心络胶囊联合阿司匹林组(A组)150例,予通心络胶囊0.52g,3次/日,阿司匹林300mg/d;华法林组(B组)150例,予华法林1.25～5.0mg/d,维持国际标准化比值1.8～2.5;阿司匹林组(C组)150例,予阿司匹林300mg/d,所有患者均给予基础疾病治疗,随访2年,以脑栓塞发病率作为疗效判定依据.结果 脑栓塞年发病率A组8.0%,B组4.0%(两组比较X2=4.5455,P=0.0330),C组14.0%(与A组比较X2=6.2937,P=0.0121).华法林组有2例出现脑出血,1例出现上消化道出血,其余两组无出血副作用.结论 通心络胶囊联合阿司匹林预防AF患者脑栓塞的效果不如华法林,优于单用阿司匹林,无严重不良反应发生,安全,且不需检测INR.
目的 比較通心絡膠囊聯閤阿司匹林、阿司匹林和華法林預防心房顫動(AF)患者腦栓塞的療效和不良反應.方法 AF患者450例,隨機分為通心絡膠囊聯閤阿司匹林組(A組)150例,予通心絡膠囊0.52g,3次/日,阿司匹林300mg/d;華法林組(B組)150例,予華法林1.25～5.0mg/d,維持國際標準化比值1.8～2.5;阿司匹林組(C組)150例,予阿司匹林300mg/d,所有患者均給予基礎疾病治療,隨訪2年,以腦栓塞髮病率作為療效判定依據.結果 腦栓塞年髮病率A組8.0%,B組4.0%(兩組比較X2=4.5455,P=0.0330),C組14.0%(與A組比較X2=6.2937,P=0.0121).華法林組有2例齣現腦齣血,1例齣現上消化道齣血,其餘兩組無齣血副作用.結論 通心絡膠囊聯閤阿司匹林預防AF患者腦栓塞的效果不如華法林,優于單用阿司匹林,無嚴重不良反應髮生,安全,且不需檢測INR.
목적 비교통심락효낭연합아사필림、아사필림화화법림예방심방전동(AF)환자뇌전새적료효화불량반응.방법 AF환자450례,수궤분위통심락효낭연합아사필림조(A조)150례,여통심락효낭0.52g,3차/일,아사필림300mg/d;화법림조(B조)150례,여화법림1.25～5.0mg/d,유지국제표준화비치1.8～2.5;아사필림조(C조)150례,여아사필림300mg/d,소유환자균급여기출질병치료,수방2년,이뇌전새발병솔작위료효판정의거.결과 뇌전새년발병솔A조8.0%,B조4.0%(량조비교X2=4.5455,P=0.0330),C조14.0%(여A조비교X2=6.2937,P=0.0121).화법림조유2례출현뇌출혈,1례출현상소화도출혈,기여량조무출혈부작용.결론 통심락효낭연합아사필림예방AF환자뇌전새적효과불여화법림,우우단용아사필림,무엄중불량반응발생,안전,차불수검측INR.
Objective To comparison of the efficacy and safety of usage of Tongxinluo capsule combination with Aspirin, Warfarin and Aspirin to prevent Cerebral thromboembolism due to atrial fibrillation(AF).Methods 450 patients with AF were divided into 3 groups randomly. Patients of Tongxinluo capsule combination with Aspirin grop(n=150) were dis-pensed by Tongxinluo capsule(0.52g/day) and Aspirin (0.3g/day).Patients of Warfarin group (n=150) were dispensed by Warfarin, The range of dosage was 1.25～5mg/day and Keep the INR between 1.8 and 2.5. Patients of Aspirin group(n=150) were dispensed by Aspirin (0.3g/day). The primary disease of all patients was intervention. Clinical prognosis of the three groups such as Cerebral thromboembolism and side effect were followed up 2 years. Results The incidence rate of Cerebral thromboembolism in Tongxinluo capsule combination with Aspirin grop(8.0%/year) was difference than in Warfarin group(4.0%/year, x2=4.5455, P=0.0330) and significantly lower than in aspirin grop(14.0%/year, x2=6.2937, P=0.0121). The inci-dence rate of hemorrage in Warfarin group was 1.0%/year (n=3)and it was zero in the other two grops (x2=1.3468, P=0.2458). Conclusion The effect of usage of Tongxinluo capsule combination with Aspirin to prevent Cerebral thromboembolism due to AF is no better than usage of Warfarin and significantly better than usage of Aspirin. It is safe using Tongxinluo capsule combination with Aspirin to prevent Cerebral thromboembolism due to AF,and it does not need detect INR.
